comparemela.com
Home
Live Updates
Long-Term Follow-Up Data Show Consistent, Durable Response to Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy : comparemela.com
Long-Term Follow-Up Data Show Consistent, Durable Response to Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy
Results from the VALOR-HCM LTE trial at 56 weeks demonstrated that with longer follow-up, mavacamten continued to reduce patient eligibility for invasive septal reduction therapy.
Related Keywords
Madrid
,
Spain
,
United States
,
Amy Sehnert
,
Pablo Garcia Pavia
,
Milind Desai
,
York Heart Association
,
Thoracic Institute At Cleveland Clinic
,
Bristol Myers Squibb
,
European Union
,
New York Heart Association
,
Hypertrophic Cardiomyopathy
,
Thoracic Institute
,
Cleveland Clinic
,
Inherited Cardiac Diseases
,
Heart Failure Unit
,
Hospital Universitario Puerta De Hierro
,
comparemela.com © 2020. All Rights Reserved.